The clinical case of a combined new coronavirus infection and whooping cough in an unvaccinated child.

Whooping cough remains a life-threatening infection, especially for unvaccinated young children. The article describes a case of severe and non-smooth course of whooping cough in an unvaccinated, girl of 4 months of life from the family hearth of whooping cough and. COVID-19. There were cases of COVID-19 and. whooping cough, in adults in the family, occurring under the mask of a mild respiratory infection, not verified before they were detected, in a child, and. did. not require hospitalization. The combined, course of two infectious diseases COVID-19 and. whooping cough, in a 4-month-old. unvaccinated, girl contributed, to the prolongation of the duration o f whooping cough, prolonged release o f SARS-COV-2 RNA, the late appearance of hematological changes typical o f whooping cough, the development o f respiratory delays and re-hospitalization o f a patient with prolonged respiratory support. In the context of the COVID-19 pandemic, the coverage of routine vaccination, has significantly decreased, as a result of which, children of the first years of life have become more vulnerable to vaccine-controlled, infections, which, causes the risk of combined, infections.Copyright © 2022 Authors. All rights reserved.

Routine vaccination coverage - worldwide, 2021

This article discusses the worldwide routine vaccination coverage in 2021, as part of the Immunisation Agenda 2030, a global immunisation strategy to reduce morbidity and mortality from vaccine-preventable diseases. The report presents global, regional, and national estimates and trends in vaccination coverage through 2021, based on reviews of country-specific data, including administrative and survey-based coverage. Global estimates show that coverage with 3 doses of diphtheria, tetanus and pertussis-containing vaccine (DTPcv3) and the first dose of measles-containing vaccine (MCV1) decreased to their lowest levels since 2008. In 2021, 25.0 million infants were not vaccinated with DTPcv3, 2.1 million more than in 2020, and 5.9 million more than in 2019. The number of zero-dose children was 37% higher than in 2019, with 18.2 million infants not receiving any DTPcv dose by the age of 12 months. The report highlights that the full recovery from disruptions to immunisation programmes due to the COVID-19 pandemic will require context-specific strategies to find missed children, prioritise essential health services, and strengthen immunisation programmes to prevent outbreaks.

The clinical case of a combined new coronavirus infection and whooping cough in an unvaccinated child.

Whooping cough remains a life-threatening infection, especially for unvaccinated young children. The article describes a case of severe and non-smooth course of whooping cough in an unvaccinated, girl of 4 months of life from the family hearth of whooping cough and. COVID-19. There were cases of COVID-19 and. whooping cough, in adults in the family, occurring under the mask of a mild respiratory infection, not verified before they were detected, in a child, and. did. not require hospitalization. The combined, course of two infectious diseases COVID-19 and. whooping cough, in a 4-month-old. unvaccinated, girl contributed, to the prolongation of the duration o f whooping cough, prolonged release o f SARS-COV-2 RNA, the late appearance of hematological changes typical o f whooping cough, the development o f respiratory delays and re-hospitalization o f a patient with prolonged respiratory support. In the context of the COVID-19 pandemic, the coverage of routine vaccination, has significantly decreased, as a result of which, children of the first years of life have become more vulnerable to vaccine-controlled, infections, which, causes the risk of combined, infections.Copyright © 2022 Authors. All rights reserved.

The clinical case of a combined new coronavirus infection and whooping cough in an unvaccinated child.

Whooping cough remains a life-threatening infection, especially for unvaccinated young children. The article describes a case of severe and non-smooth course of whooping cough in an unvaccinated, girl of 4 months of life from the family hearth of whooping cough and. COVID-19. There were cases of COVID-19 and. whooping cough, in adults in the family, occurring under the mask of a mild respiratory infection, not verified before they were detected, in a child, and. did. not require hospitalization. The combined, course of two infectious diseases COVID-19 and. whooping cough, in a 4-month-old. unvaccinated, girl contributed, to the prolongation of the duration o f whooping cough, prolonged release o f SARS-COV-2 RNA, the late appearance of hematological changes typical o f whooping cough, the development o f respiratory delays and re-hospitalization o f a patient with prolonged respiratory support. In the context of the COVID-19 pandemic, the coverage of routine vaccination, has significantly decreased, as a result of which, children of the first years of life have become more vulnerable to vaccine-controlled, infections, which, causes the risk of combined, infections.Copyright © 2022 Authors. All rights reserved.

Vaccination against whooping cough in pregnancy: evaluation of an organizational proposal implemented between 2018 and 2022 in the health district of urban area of Pisa (italy) and a method for coverages calculation

Introduction: Vaccination against Bordetella pertussis is recommended by the Italian Ministry of Health starting from the 28th week of pregnancy. However, data about vaccine coverages are unknown and sharing good practices is necessary to increase adherence to vaccine programs implemented at local level. Here we present data on epidemiology and vaccine coverage of Pertussis in Tuscany from 2012 to 2021 and data on Pertussis vaccine coverage in pregnant women in the Health District of urban area of Pisa for the period 2017 to September 2022. Materials and methods: Data on pertussis cases and pertussis vaccine coverage were retrieved form the Regional Health Agency that made available data on Infectious Diseases Epidemiology in Tuscany on a public report. The diphteria, tetanus, pertussis (dTpa) vaccination in pregnant women were extracted from the vaccination registry from 2017 to 30 September 2022 and adjusted new births from 1st April to 30th March of the following year were considered as denominator. For the current year we assumed that the monthly trend of the absolute number of vaccinations is maintained (+45.3 vaccinations/month) and that the number of new-borns is the same as in 2021. Results: In Tuscany, a progressive increase in the number of cases has been observed since 2012, peaking in 2017 with 115 infections concentrated mainly in children under one year of age. After a significant reduction in the three-year period 2018-2020, with values between 25 and 39 infections per year, no cases of the disease were notified in 2021. Most likely due to the actions taken to counteract the transmission of SARS-CoV-2. Notably, from 2017 to 30 September 2022, a significant increase in vaccination coverage for dTpa in pregnant women was observed, with an average annual increase from 2018 onwards of 39% (range 18%-63%). Discussion and conclusions: Even if the vaccine coverage calculation has some limitations, the availability of a free access services for pregnant women and their contacts has improved adherence to the vaccination against pertussis. However, to achieve an active recruitment strategic to overcome cultural, linguistic and hesitancy barriers it is crucial to improve active call of the pregnant women.

Enhancing vaccination of key populations: lessons and actions

Vaccination is effective in preventing the increase of disease, especially emerging infectious diseases (EIDs), and it is particularly important for people in close contact with infected sources and susceptible populations who are at increased risk of getting infectious diseases due to behavior, occupation or health. Despite targeted vaccination guidelines, inadequate vaccination of the key populations fails to receive widespread attention, resulting in a high-risk transition of disease from key populations to general populations. Strengthening the vaccination of the susceptible groups can effectively block the spread of pathogens to general populations, and reduce the consumption of medical resources in universal vaccination, which has significant economic value. In this review, we describe the prevalence of EIDs, analyze the experience and lessons of infectious disease vaccination in key populations through several cases, and further explore the causes for the decline in vaccination rates of key populations. According to the trends of EIDs, a plan to strengthen the vaccination of key populations is proposed to effectively prevent the transition of EIDs from key populations to general populations.

Unique opportunity for double protection: vaccination during pregnancy.

Vaccinations are one of the greatest achievements for protecting public health. Vaccines given to pregnant women protect not only the pregnant woman, but also the newborn. Pregnant women are disproportionately strongly affected by infections. The conflicting demands on the maternal immune system during pregnancy geared toward maintaining fetal immune tolerance make a rapid and effective immune response against pathogens more difficult. This dynamic state of immune adaptation predisposes pregnant women to more severe disease progression. Vaccination can prevent infection or a serious course of disease. As a result, the risk of premature birth and other serious pregnancy complications that can have lifelong consequences for both mother and child also decreases. After birth, when the newborn must first develop an adaptive memory for a hitherto unknown, antigen-rich environment, it is particularly vulnerable to infections and resulting complications. The transfer of maternal antibodies across the placenta protects infants who are too young to be vaccinated. When breastfeeding, this continues through antibodies in breast milk. For the vaccinations recommended by the Standing Vaccination Committee (STIKO) during pregnancy (influenza, pertussis, coronavirus disease [COVID]-19), there is clear evidence from various observational and prospective studies that they protect mother and child either from infection or from a severe disease course. The following article gives an overview of the vaccination strategy for pregnancy and summarizes the scientific data on effectiveness of the vaccinations currently recommended during pregnancy.Copyright © 2022, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Acceptance of vaccination against pertussis, COVID-19 and influenza during pregnancy: a cross-sectional study.

BACKGROUND: This study aims to assess the uptake of maternal pertussis and COVID-19 vaccination and the intention towards accepting the maternal influenza vaccination. Insights into different socio-demographic factors related to maternal vaccination coverage might help to address vaccine acceptance and improve maternal vaccine uptake in the future. METHODS: We conducted a cross-sectional survey among pregnant women and recent mothers, up to 6 months post-partum. The primary outcome measures of this study were behaviour for maternal pertussis and COVID-19 vaccination, and maternal influenza vaccination intention. Associations between socio-demographic factors and maternal pertussis vaccination and maternal COVID-19 vaccination behaviour; and socio-demographic factors and maternal influenza vaccination intention were assessed using binary logistic regression analyses. RESULTS: In total 1361 respondents filled out the questionnaire. Almost all women (95%) were vaccinated against pertussis during pregnancy, while almost two-third were vaccinated against COVID-19 during pregnancy (58%) and almost one-third (28%) had a positive intention towards receiving the maternal influenza vaccination. Results show that young maternal age and low education level were associated with lower maternal vaccination acceptance. CONCLUSION: Vaccination campaigns focusing on the severity of diseases that are prevented, are needed to increase maternal vaccine acceptance in younger and low-educated pregnant women. We expect that differences in vaccination coverage between the three maternal vaccinations might partly be explained by existing recommendations, campaigns and whether the vaccination is part of the national immunisation program.

Td/Tdap Vaccine Recommendation in a Previously Healthy Adolescent Pregnant?: Journal of Pediatric Infection

According to the 2018 Hacettepe University Population and Health Survey report, of the married women between 25-49 age group;39% get married before the age of 20, 21% before the age of 18 and 4% before the age of 15 (1). According to the WHO report, in 2019, abortion was reported at a rate of 55% in unplanned pregnancies in adolescents, especially in countries with limited resources (2). According to CDC data, it has been reported that the Tdap vaccine administered in the 27-36 weeks of the pregnancy, reduces pertussis disease by 78% in the first two months of their infants, and it reduces the infant hospitalizations due to whooping cough by 90% (6-8). [...]the first dose is given at the first visit, the second dose is administered four weeks later, the third dose is given 6-12 months after the second dose, and the vaccination schedule is completed in three doses (3,8).

Einmalige Möglichkeit für doppelten Nutzen: Impfungen in der Schwangerschaft

Vaccinations are one of the greatest achievements for protecting public health. Vaccines given to pregnant women protect not only the pregnant woman, but also the newborn. Pregnant women are disproportionately strongly affected by infections. The conflicting demands on the maternal immune system during pregnancy geared toward maintaining fetal immune tolerance make a rapid and effective immune response against pathogens more difficult. This dynamic state of immune adaptation predisposes pregnant women to more severe disease progression. Vaccination can prevent infection or a serious course of disease. As a result, the risk of premature birth and other serious pregnancy complications that can have lifelong consequences for both mother and child also decreases. After birth, when the newborn must first develop an adaptive memory for a hitherto unknown, antigen-rich environment, it is particularly vulnerable to infections and resulting complications. The transfer of maternal antibodies across the placenta protects infants who are too young to be vaccinated. When breastfeeding, this continues through antibodies in breast milk. For the vaccinations recommended by the Standing Vaccination Committee (STIKO) during pregnancy (influenza, pertussis, coronavirus disease [COVID]-19), there is clear evidence from various observational and prospective studies that they protect mother and child either from infection or from a severe disease course. The following article gives an overview of the vaccination strategy for pregnancy and summarizes the scientific data on effectiveness of the vaccinations currently recommended during pregnancy.

Routine vaccination coverage - worldwide, 2020

This report, which updates previous reports, presents estimates of global, regional, and national vaccination coverage and trends as of 2020. It describes the changes in vaccination coverage and the numbers of unvaccinated and undervaccinated children as measured by receipt of the first and third doses of diphtheria, tetanus, and pertussis-containing vaccine (DTP)in 2020, when the COVID-19 pandemic began, compared with 2019. Global coverage estimates with the third dose of DTP (DTP3) and a polio vaccine (Pol3) fell from 86% in 2019 to 83% in 2020. Similarly, MCV1 coverage fell from 86% in 2019 to 84% in 2020. The last year the coverage estimates were at 2020 levels was 2009 for DTP3 and 2014 for both MCV1 and the third dose of Pol (Pol3). Worldwide, 22.7 million children(17% of the target population) did not receive DTP in 2020, compared with 19.0 million (14%) in 2019. Children who did not receive the first DTP dose (DTP1) by age 12 months (zero-dose children) accounted for 95%of the increased number. Among those who did not receive DTP3 in 2020, approximately 17.1 million (75%)were zero-dose children. Global coverage decreased in 2020 compared with 2019 estimates for the completion of Haemophilus influenzae type b (Hib), hepatitis B vaccine (HepB), human papillomavirus vaccine (HPV),and rubella-containing vaccine (RCV). To reach full coverage with all recommended vaccines, tailored strategies will be needed, especially to reach communities with a lot of children who haven't had any or enough vaccines.

Risk assessment of public health emergencies concerned in the mainland of China, April 2022

Objective To assess the risk of public health emergencies, both the indigenous ones and the imported ones, which might occur in the mainland of China in April 2022. Methods An internet based expert counsel was conducted to analyze the surveillance data of public health emergencies and priority communicable diseases in China reported through different channels, and the experts in all provincial centers for disease control and prevention attended this video conference. Results It is expected that number of domestically reported public health emergency events other than COVID-19 in April would remain unchanged from March. The risk of domestic COVID-19 outbreaks caused by the indigenous transmission and the foreign importation is high, making it more difficult to prevent and control the epidemic. Local governments need to strengthen epidemic prevention and control in accordance with national requirements and hold the bottom line of no large-scale rebound of the epidemic. The number of pertussis cases will maintain rising trend due to the improvement of laboratory testing technology, the weakening of vaccine protection and the strengthening of surveillance in some districts. Conclusion Special attention should be paid to COVID-19. General attentions should be paid to pertussis.

EVALUATION OF THE LEVEL OF COLLECTIVE IMMUNITY IN CHILDREN LIVING IN THE CITY OF YEKATERINBURG TO VACCINE-PREVENTABLE INFECTIONS AGAINST THE BACKDROP OF THE SPREAD OF THE COVID-19 PANDEMIC.

The vaccination is recognized as one of the most effective and cost-effective measures to prevent the emergence and spread of infectious diseases. There is a possibility that the COVID-19 pandemic may lead to disruption of the vaccination campaign against vaccine-preventable infections and the formation of herd immunity. The aim of the study is to assess the level of collective immunity to vaccine-preventable infections in children living in the city of Yekaterinburg, Russia, against the backdrop of the COVID-19 pandemic. Research materials and methods: an observational cohort retrospective study was conducted, which included the results of a survey of 520 children aged 1 to 18 years old in 2021 for the presence of antibodies (AB) to the pathogens of measles, whooping cough, mumps, diphtheria and poliomyelitis. As a comparison the study used materials from a survey of children conducted in 2007–2013 for the assessment of herd immunity to vaccinepreventable infections (n=298). So the total number of children examined was 818. Results: the proportion of seronegative individuals examined for the presence of IgG to the causative agent of diphtheria among children aged 1 to 6 years old was 6.3%, 7 to 14 years old – 4.0%, 15 to 17 years old – 0.7 % (p<0.001). The proportion of children with no antibodies to the measles virus is 11.9%, 7.6%, and 12.4%, respectively, in the age groups of 1 to 6/7 to 14/15 to 17 years old (p=0.02). The proportion of seronegative to the mumps virus among children of different ages lays within 12% to 23.8%. The share of children with the absence of protective antibody titers to the whooping cough pathogen was 51.1% in children aged 15 to 17 years old, 69.5% for 7 to 14 years old, and 62.5% for 1 to 6 years old (p<0.001). With a cut-off of 10%, the proportion of children unprotected from type I poliovirus was 9.1% in the 3 to 5 years old age group and 6.8% in the 11 to 17 years old age group. The proportion of seronegative to poliovirus type III was 11.2% and 23.9%, respectively, in the younger and older groups of children. Discussion: the most favorable state of herd immunity was found in relation to diphtheria. Alertness is caused by immunity to measles and mumps. The most alarming is the state of herd immunity to whooping cough. Conclusion: for the period 2012– 2021 there was an increase in the number of children with protective antibodies to the pathogens of diphtheria, measles, mumps, and whooping cough. However, with the exception of diphtheria, in all of these infectious diseases, the level of seronegative individuals exceeds the recommended thresholds. A high proportion of seronegative individuals increases the risk of the emergence and spread of infectious diseases. (English) [ FROM AUTHOR] Вакцинопрофилактика признана одной из самых эффективных и экономически целесообразных мер по предупреждению возникновения и распространения инфекционных заболеваний. Существует вероятность, что пандемия COVID-19 может привести к нарушениям прививочной кампании от вакциноуправляемых инфекций и формирования коллективного иммунитета. Цель исследования – оценить уровень коллективного иммунитета к вакциноуправляемым инфекциям у детей г. Екатеринбурга на фоне пандемии COVID-19. Материалы и методы исследования: проведено наблюдательное когортное ретроспективное исследование, в которое вошли результаты обследования 520 детей в возрасте от 1 года до 18 лет в 2021 г. на наличие у них антител (АТ) к возбудителям кори, коклюша, эпидемического паротита, дифтерии и полиомиелита. Кроме того, для сравнения в работе использованы материалы обследования детей в период 2007–2013 гг. по оценке коллективного иммунитета к вакциноуправляемым инфекциям (n=298). Общее количество обследованных – 818. Результаты: удельный вес серонегативных лиц, обследованных на наличие IgG к возбудителю дифтерии, среди детей 1–6 лет составил 6,3%, 7–14 лет – 4,0%, 15–17 лет – 0,7% (p<0,001). Доля детей с отсутствием АТ к вирусу кори – 11,9%, 7,6% и 12,4% соответственно в возрастных группах 1–6 лет, 7–14 лет и 15–17 лет (p=0,02). Процент серонегативных к вирусу эпидемического паротита среди детей разного возраста – в пределах 12–23,8%. Удельный вес детей с отсутствием защитных титров АТ к возбудителю коклюша составил 51,1% у детей 15–17 лет, 69,5% у детей 7–14 лет и 62,5% у детей 1–6 лет (p<0,001). При пороговом значении 10% доля детей, незащищенных от полиовируса I типа, составила 9,1% в возрастной группе 3–5 лет и 6,8% в возрастной группе 11–17 лет. Удельный вес серонегативных лиц к полиовирусу III типа составил 11,2% и 23,9% соответственно в младшей и старшей группах детей. Обсуждение: наиболее благоприятное состояние коллективного иммунитета выявлено в отношении дифтерии. Настороженность вызывает иммунитет к кори и эпидемическому паротиту. Наиболее тревожным является состояниеколлективного иммунитета к коклюшу. Заключение: за период 2012–2021 гг. отмечено увеличение количества детей, имеющих защитные АТ к возбудителям дифтерии, кори, эпидемического паротита, коклюша. Однако за исключением дифтерии, при все … названных инфекционных заболеваниях уровень серонегативных лиц превышает рекомендуемые пороговые значения. Высокая доля серонегативных лиц повышает риск возникновения и распространения инфекционных заболеваний. (Russian) [ FROM AUTHOR] Copyright of Pediatriya named after G. N. Speransky is the property of Pediatria, Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

A Review On Application Of Deep Learning For Lung Infection Detection On Different Medical Images

Infectious diseases in the respiratory system are a significant source of death and disability across the world. Despite the fact that radiology is the main diagnostic technique for monitoring lung related infections, visual analysis of MRI's and computerized tomography (CT) scans is confined due to low quality for causational potential pathogens and a restricted ability to evaluate severity and anticipate health outcomes. Herein, in this paper a review on the imaging characteristics and computing models that have been applied for the management of COVID-19 are presented such as CT positron emission tomography-CT (PET/CT), magnetic resonance imaging (MRI), Fluorodeoxyglucose (FDG)-positron emission tomography (PET) have been used for detection, treatment, and follow-up. Also, highlight the limitations of identifying and characterizing these illnesses using Medical Imaging with deep learning, and provide potential solutions to these problems. Thus, this paper gives special attention to the role of Deep learning and various Medical Imaging techniques in the diagnosis and therapy monitoring of infectious and inflammatory diseases. Enough evidence in the literature already exists about the usefulness of FDG-PET/CT in the diagnosis and management of patients.

Effect of pertussis vaccine in pregnancy and COVID-19 pandemic in the cases of wooping cough.

BACKGROUND: Whooping cough has had an increased incidence and severity specially in infants and maternal immunization has been implemented as a prevention strategy. COVID-19 pandemic seems to decrease the incidence of other respiratory diseases. METHODS: Retrospective study from 2012 to 2021 to assess the influence of pertussis maternal immunizations and the first year of COVID-19 pandemic in the cases of whooping cough. RESULTS: 960 suspected cases from primary care and hospital, with 130 cases (104 children and 26 adults) being diagnosed of whooping cough. In the post-vaccination period, a reduction in the cases and severity in infants up to 6 months old was observed as well as in the pertussis diagnosis in adult women. There were no whooping cough cases during the COVID-19 period. CONCLUSIONS: Both the pertussis vaccination in pregnancy and the first year of the COVID-19 pandemic have decreased the number of pertussis cases.

Exploring national COVID-19 variability across sub-Saharan Africa

Background: In early March 2020, coronavirus disease (COVID-19), an infectious disease caused by a novel coronavirus, was declared a pandemic by the World Health Organization. Since its emergence and global spread, the pandemic has been one of the greatest global crises in modern human history. Notably, in Sub-Saharan Africa (SSA), COVID-19-related burden and outcomes have been generally lower than many other parts of the world and substantially better than were initially feared. At the same time, there has been great heterogeneity in COVID-19 burden and outcomes between countries in the region, with some reporting particularly high incidence and death figures compared to others. What accounts for the significant cross-country variability apparent in SSA and why have some countries performed better than others? The present study investigates country-specific factors that may help to explain differences in COVID-19 outcomes across 48 countries in SSA.

Impact of fulfilling immunization coverage during the COVID-19 pandemic: a systematic review

Introduction: Indonesia reported the first case of COVID-19, the coverage of routine immunization to prevent diseases in children such as measles, rubella, and diphtheria is decreasing. For example, diphtheria, pertussis and tetanus (DPT3) and measles and rubella (MR1) immunization coverage rates were reduced by more than 35% in May 2020 compared to the same time period in the previous year.

An agile discovery method of drugs for infectious diseases and tentative exploration of its application in drug discovery for COVID-19

OBJECTIVE: To establish an agile discovery method of drugs or natural products for epidemics (aCODE) for the development of anti-infectious disease drugs. METHODS: Five infectious diseases (HIV infection, human influenza, Paramyxoviridae infections, bacterial infections and whooping cough) involving more than 40 drugs approved by the United States Food and Drug Administration (FDA) were selected. An experimental group and two negative control groups (A and B) for each disease were set up. The experimental group randomly selected (500 times) M FDA-approved indications as seed drugs for the disease, while negative control group A used all FDA-approved infectious drugs for non-current diseases instead of seed drugs, and negative control group B used all non-infectious disease drugs for non-infectious diseases instead of seed drugs. M ranged from 2 to 20, the target gene information of the seed drug was input, and the feature vector of the seed drug set was calculated. Candidate compounds were predicted through similarity search of drug feature vectors. The size of the inter- section between the predicted drug and the positive set of drugs approved by the FDA for the disease, and the significance of the intersection were calculated. After the establishment of the aCODE method, four drugs (lopinavir, ribavirin, ritonavir and chloroquine) were selected as seed drugs for COVlD-19 to predict the composition of natural products. Using natural products with known anti-coronavirus activities as the verification set, the significance of the prediction results was calculated. RESULTS: In the case of the five infectious diseases, the proportion of positive drugs in the results of prediction in the experimental group increased with the number of seed drugs, while the positive rate of the two negative control groups remained basically unchanged or somewhat trended down. The aCODE method, when applied to COVlD-19 drug screening, could effectively predict drugs with potential anti-SARS-Cov-2 activity (P=0.0046). CONCLUSION: With the aCODE method, the more the seed drugs, the more accu- rate the characteristics of the disease-related gene modules calculated from this group of seed drugs, and the higher the proportion of positive drugs in the prediction result. This method may contribute to the discovery of drugs for COVID-19.